Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2024-02-14 Notice of Dividend Amou…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
EQS-News: Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenrendite im 2024
Notice of Dividend Amount Classification · 99% confidence The document is a news release from BB BIOTECH AG, identified by the EQS-News header. The primary focus of the text is the announcement of a proposed dividend of CHF 2.00 at the upcoming General Meeting on March 21, 2024, and the resulting high dividend yield. It also discusses market conditions and portfolio updates. Since the core subject is the proposed dividend amount and the associated shareholder meeting date, this strongly aligns with the 'Notice of Dividend Amount' (DIV). While it mentions the AGM date, the main actionable financial item announced is the dividend proposal, not the AGM materials themselves (AGM-R) or the voting results (DVA). It is not a full financial report (10-K or IR) nor a general earnings release (ER).
2024-02-14 German
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' dated January 19, 2024, disclosing preliminary financial results for the full year 2023 and announcing changes to the Board of Directors (including a director not standing for re-election and proposals for successors at the upcoming AGM). Since it contains both preliminary financial highlights (Loss of CHF 207 mn for FY 2023) and significant management/board changes, it covers elements of both Earnings Release (ER) and Board/Management Information (MANG). However, the primary function of this specific announcement, as indicated by the headline and content structure, is to immediately communicate key financial performance metrics alongside personnel news. Given the dual nature, and the fact that it is an immediate release of preliminary results, 'ER' (Earnings Release) is a strong candidate, but 'MANG' (Board/Management Information) is also highly relevant due to the detailed director changes. Since the document explicitly states the full annual report will be published later (Feb 16, 2024), it is not the 10-K. Because it contains significant personnel changes (director stepping down, successor proposed), 'MANG' is a very specific fit. If forced to choose the most specific category covering the personnel aspect, MANG applies. If focusing on the financial highlights, ER applies. Since the document explicitly mentions both 'financial results' and 'changes to the Board of Directors' in the title, and the content dedicates significant space to both, I will prioritize the management change aspect as it is a specific, non-standard element often separated from a pure ER. However, the immediate release of preliminary annual figures strongly suggests ER. Given the explicit mention of both, and the fact that the financial results are preliminary, ER is often used for the initial release of period results. Let's re-evaluate: The document announces both 'financial results for 2023' and 'changes to the Board of Directors'. Both ER and MANG apply. In many databases, an announcement containing both is often classified by the most significant event or the one that triggers the ad-hoc requirement. Since the financial results are preliminary and the board changes are significant, I will classify this as MANG because the board changes are detailed and specific to director succession, which is a core MANG topic, while the financial data is preliminary and points to a later full report. Alternatively, if the financial results are the primary driver, ER is appropriate. Given the structure, I lean towards MANG due to the specific director succession details being presented as equally important as the preliminary results. Upon final review, the document is a hybrid. Since the financial results are preliminary and the board changes are detailed, MANG is the most specific fit for the personnel aspect, which is often a separate disclosure requirement. I will select MANG. FY 2023
2024-01-19 English
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
Earnings Release Classification · 100% confidence The document is an announcement released via EQS-News, titled 'BB BIOTECH AG / Key word(s): Annual Results/Dividend'. It summarizes the company's performance for the year ending December 31, 2023, including portfolio gains/losses, net loss, and proposes a dividend at the upcoming Annual General Meeting (AGM) on March 21, 2024. It also announces changes to the Board of Directors. Crucially, the text explicitly states: 'The complete annual report as of December 31, 2023, will be published on February 16, 2024.' This indicates the current document is a preliminary summary or release of annual results, not the full Annual Report (10-K) or the comprehensive Interim/Quarterly Report (IR). Since it contains key financial highlights, dividend proposal, and management/governance changes related to the year-end, it aligns best with an Earnings Release (ER) or a document summarizing annual results before the full report is out. Given the focus on year-end results and the dividend proposal, 'ER' (Earnings Release) is the most appropriate fit for this type of preliminary annual summary announcement, even though it is more detailed than a typical quarterly ER. It is not a formal 10-K, AR, or a simple RPA/RNS because it contains substantial narrative analysis and data. FY 2023
2024-01-19 English
EQS-News: BB Biotech AG: Jahresendrally des Biotechsektors durch M&A-Aktivitäten und Zinswende beflügelt
Earnings Release Classification · 100% confidence The document is titled 'BB BIOTECH AG / Schlagwort(e): Jahresergebnis/Dividende' and contains a detailed summary of the company's performance for the year ending December 31, 2023, including net loss, portfolio performance, and dividend proposal. This content strongly suggests a preliminary earnings announcement or a summary of the annual results. However, the text explicitly states: 'Der vollständige Jahresbericht per 31. Dezember 2023 wird am 16. Februar 2024 veröffentlicht.' This indicates the document itself is not the final, comprehensive Annual Report (10-K) but rather an early release of the key financial figures and management commentary for the period. This fits the definition of an Earnings Release (ER), which provides initial announcements of periodical financial results (key highlights only). It also mentions dividend proposals and management changes, which are common in ERs. Since it is a release of results, ER is the most appropriate code, rather than RPA (which announces the publication of a report that is not yet attached/provided). FY 2023
2024-01-19 German
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
Board/Management Information Classification · 95% confidence The document is an 'Ad hoc announcement' published on January 19, 2024, disclosing two main pieces of information: preliminary financial results for 2023 and changes to the Board of Directors (resignation and proposed successors). The text explicitly states that the complete annual report will be published later (February 16, 2024), and the preliminary results are announced here. The announcement covers both financial performance highlights (ER territory) and management/board changes (MANG territory). Since it is an immediate, short announcement highlighting key results and management changes, and it is not the full report itself, it fits best as an Earnings Release (ER) which often includes key operational/management updates, or potentially a combination. However, the management/board changes are significant enough to warrant consideration for MANG. Given the structure of these ad-hoc releases, which prioritize the immediate financial outcome (even if preliminary) alongside other material news, ER is a strong candidate. Crucially, it also announces changes to the Board of Directors (Dr. Hunziker stepping down, Dr. von Planta proposed as successor). Since the document explicitly covers both 'Annual Results' and 'Personnel' changes, and it is a short, immediate disclosure, it is a hybrid. In many regulatory contexts, the initial release of financial highlights is classified as ER. The board changes strongly suggest MANG. Since the document is short (3838 chars) and serves as an immediate notification of material events, it is best classified based on the most significant immediate impact or by using the most appropriate specific category. The board changes are detailed and specific. I will prioritize the management change aspect (MANG) as it involves specific director nominations and departures, which is a distinct category, even though financial highlights are present. If the financial highlights were the sole focus, ER would be chosen. If it were just announcing the *publication* of the full report, RPA would be chosen. Since it contains substantive news on both fronts, and MANG is a specific category for board changes, I select MANG, acknowledging the ER component. Upon re-evaluation, the document is titled 'BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors'. Since it contains both key elements, and the financial results are preliminary, ER is often used for the initial release of period results. However, the detailed discussion of director succession strongly points to MANG. Given the dual nature, and the fact that MANG is a specific category for board changes, I will classify it as MANG, as the board changes are a major, non-standard event.
2024-01-19 English
EQS-Adhoc: BB Biotech AG publiziert Geschäftsergebnis 2023 und gibt Veränderungen im Verwaltungsrat bekannt
Earnings Release Classification · 99% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) published on January 19, 2024. It serves two primary purposes: 1) Announcing the preliminary 'Geschäftsergebnis 2023' (Business result for 2023), which is an initial release of financial performance, and 2) Announcing significant changes in the 'Verwaltungsrat' (Board of Directors), including resignations and proposed successors for the upcoming General Meeting. Since it announces preliminary results (stating the full report is coming later) and management/board changes simultaneously, it is a hybrid announcement. The most specific category covering board changes is 'Board/Management Information' (MANG). However, the document also contains an 'Earnings Release' component (announcing the CHF 207M loss for 2023). Given that the document is short (4057 chars) and functions as an immediate regulatory disclosure covering both key events, it fits best as an immediate regulatory announcement. Since it explicitly announces management changes (Dr. Hunziker stepping down, Dr. von Planta proposed as President), MANG is highly relevant. Since it is an immediate, mandatory disclosure (Ad hoc-Mitteilung), and it covers management changes, MANG is the most precise fit among the options that cover specific content, rather than just being a general 'RNS' or an announcement of a report ('RPA'). The mention of management changes strongly points to MANG. FY 2023
2024-01-19 German

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.